Puhr Hannah Christina, Preusser Matthias, Prager Gerald, Ilhan-Mutlu Aysegül
Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Comprehensive Cancer Center Vienna-Gastroesophageal Tumors Unit, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Cancers (Basel). 2020 Jan 28;12(2):301. doi: 10.3390/cancers12020301.
Several clinical trials attempted to identify novel treatment options for advanced gastroesophageal tumours in first, second and further lines. Although results of targeted therapy regimens were mainly disappointing, novel immunotherapy agents showed promising activity, which led to their approval in second and third lines in many countries. This review focuses on the results of recent clinical trials investigating novel agents including targeted therapies, immunotherapy components and chemotherapies and discuss their current impact as well as current approval status on the treatment armamentarium of advanced gastroesophageal tumours.
多项临床试验试图确定一线、二线及后续治疗中晚期胃食管肿瘤的新治疗方案。尽管靶向治疗方案的结果大多令人失望，但新型免疫治疗药物显示出了有前景的活性，这使得它们在许多国家被批准用于二线和三线治疗。本综述重点关注近期临床试验中研究新型药物（包括靶向治疗、免疫治疗成分和化疗）的结果，并讨论它们目前对晚期胃食管肿瘤治疗手段的影响以及当前的获批情况。
